

# Biocon Ltd. Therapeutic and Overview Pipeline Review H2

*Biocon Ltd. Treatment Pipeline Review H2 2016*

PUNE, INDIA, November 14, 2016

/EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development by Biocon Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.



WISE GUY  
REPORTS

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/740524-biocon-limited-product-pipeline-review-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

## Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Biocon Limited
- The report provides overview of Biocon Limited including its business description, key facts, and locations and subsidiaries

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Biocon Limited's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Biocon Limited's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

#### Reasons to buy

- Evaluate Biocon Limited's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Biocon Limited
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Biocon Limited's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

#### Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Biocon Limited Snapshot 5

Biocon Limited Overview 5

Key Facts 5

Biocon Limited - Research and Development Overview 6

Key Therapeutic Areas 6

Biocon Limited - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Pipeline Products - Partnered Products 11

Partnered Products/Combination Treatment Modalities 12

Biocon Limited - Pipeline Products Glance 13

Biocon Limited - Late Stage Pipeline Products 13

Pre-Registration Products/Combination Treatment Modalities 13  
Phase III Products/Combination Treatment Modalities 14  
Biocon Limited - Clinical Stage Pipeline Products 15  
Phase II Products/Combination Treatment Modalities 15  
Phase I Products/Combination Treatment Modalities 16  
Biocon Limited - Early Stage Pipeline Products 17  
Preclinical Products/Combination Treatment Modalities 17  
Biocon Limited - Drug Profiles 18  
adalimumab biosimilar - Drug Profile 18  
Product Description 18  
Mechanism Of Action 18  
R&D Progress 18  
bevacizumab biosimilar - Drug Profile 19  
Product Description 19  
Mechanism Of Action 19  
R&D Progress 19  
BVX-20 - Drug Profile 20  
Product Description 20  
Mechanism Of Action 20  
R&D Progress 20  
etanercept biosimilar - Drug Profile 21  
Product Description 21  
Mechanism Of Action 21  
R&D Progress 21  
filgrastim - Drug Profile 22  
Product Description 22  
Mechanism Of Action 22  
R&D Progress 22  
insulin aspart - Drug Profile 23  
Product Description 23  
Mechanism Of Action 23  
R&D Progress 23  
insulin glargine - Drug Profile 24  
Product Description 24  
Mechanism Of Action 24  
R&D Progress 24  
insulin human - Drug Profile 26  
Product Description 26  
Mechanism Of Action 26  
R&D Progress 26  
insulin lispro - Drug Profile 27  
Product Description 27  
Mechanism Of Action 27

R&D Progress 27  
insulin tregopil - Drug Profile 28  
Product Description 28  
Mechanism Of Action 28  
R&D Progress 28  
itolizumab - Drug Profile 30  
Product Description 30  
Mechanism Of Action 30  
R&D Progress 30

Access Report @ <https://www.wiseguyreports.com/reports/740524-biocon-limited-product-pipeline-review-2016>

Contact Info:□

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)□

Get in touch:

LinkedIn: [www.linkedin.com/company/4828928](http://www.linkedin.com/company/4828928)

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/353795097>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.